Hainan Haiyao (000566.SZ): Imipenem for injection passes generic drug quality and efficacy consistency evaluation.

Hainan Haiyao (000566.SZ) announced that its wholly-owned subsidiary, Haikou Pharmaceutical Factory Co., Ltd., recently obtained the "Drug Supplementary Application Approval Notice" for the chemical drug meropenem injection issued by the National Medical Products Administration. Meropenem is a synthetic broad-spectrum carbapenem antibiotic that works by inhibiting the synthesis of bacterial cell walls, easily penetrating the cell walls of most gram-positive and gram-negative bacteria to target its binding protein, penicillin-binding proteins (PBPs). In addition to metallo--lactamases, it has strong stability in hydrolyzing most -lactamases (including penicillinases and cephalosporinases produced by both gram-positive and gram-negative bacteria). Injectable meropenem is mainly used in adults and children for infections caused by bacteria sensitive to meropenem, including pneumonia (including nosocomial pneumonia), urinary tract infections, intra-abdominal infections, gynecological infections (such as endometritis and pelvic inflammatory disease), skin and soft tissue infections, meningitis, and sepsis.